An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway.
B Schiemann, J L Gommerman, K Vora...
https://pubmed.ncbi.nlm.nih.gov/11509691/Actively Recruiting
Led by Charles M Knudson · Updated on 2025-05-20
200
Participants Needed
1
Research Sites
521 weeks
Total Duration
Researchers are studying patients with immune-mediated diseases who undergo plasma exchange PLEX procedures to remove harmful substances, often antibodies. This study aims to collect and preserve blood samples from these patients to analyze antibody levels and immune factors over time. The goal is to better understand how plasma exchange affects normal and harmful immune components in various patients. Participants will continue their usual plasma exchange treatments without changes from the study. The study groups include patients receiving plasma as a replacement fluid and those receiving saline or 5% albumin. Blood samples such as plasma, serum, and immune cells PBMCs will be collected at multiple points during and after treatment to facilitate current and future research. During the study, participants will provide blood samples and clinical data over the treatment course, typically lasting 1-2 weeks, to track antibody levels and immune factors. The study will also follow patients after plasma exchange completion to collect additional samples. This long-term collection helps researchers monitor immune changes and supports future studies. Participation involves no alteration to treatment plans and continues until the end of the plasma exchange course.
CONDITIONS
Biorepository and Registry for Plasma Exchange Patients
C
Charles Knudson, MD, PHD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Charles M Knudson
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 1 to 2 weeks
Participants undergoing plasma exchange therapy are observed to assess changes in immune factors during treatment.
1 to 2 visits during treatment
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
B Schiemann, J L Gommerman, K Vora...
https://pubmed.ncbi.nlm.nih.gov/11509691/Hollie M Reeves, Jeffrey L Winters
https://pubmed.ncbi.nlm.nih.gov/24172059/Tamara Möckel, Fabio Basta, Julia Weinmann-Menke...
https://pubmed.ncbi.nlm.nih.gov/33333233/Jeffrey L Winters
https://pubmed.ncbi.nlm.nih.gov/23233554/Charles M Knudson
Lead Sponsor